Clinical Trial Update: A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating safety and efficacy of adding sorafenib to carboplatin and paclitaxel in chemonaive stage IIIB-IV non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Non-Small Cell Lung | Phase 3 | Status: TERMINATED | Results posted: 2010-09-20